Mansour Ahmad M, Stewart Michael W, Farah Michel E, Mansour Hana A, Chhablani Jay
Department of Ophthalmology, American University of Beirut, Beirut, Lebanon.
Department of Ophthalmology, Rafik Hariri University Hospital, Beirut, Lebanon.
Acta Ophthalmol. 2020 Aug;98(5):e540-e548. doi: 10.1111/aos.14328. Epub 2019 Dec 20.
Ziv-aflibercept (Zaltrap ), a recombinant fusion protein that binds diffusible vascular endothelial growth factor (VEGF), is approved for the treatment of metastatic colorectal carcinoma. Its molecular structure is the same as aflibercept (Eylea ), thus making it an attractive option for the off-label treatment of chorioretinal vascular conditions. Ziv-aflibercept is distributed in 4 and 8 ml vials for intravenous use, and its cost after compounding is similar to bevacizumab. Studies with retinal pigment epithelium cytotoxicity, animal histologic sections and electroretinography have demonstrated its safety, and mathematical modelling combined with over four dozen clinical publications from different ophthalmic centres throughout the world attest to its efficacy. No appreciable differences in visual or anatomic outcomes between 1.25 mg (0.05 ml) and 2.5 mg (1.0 ml) doses have been noted. The long duration of action combined with the low cost make ziv-aflibercept an attractive anti-VEGF treatment option, especially in low- and middle-income countries where its popularity is increasing.
阿柏西普（Zaltrap）是一种可结合可溶性血管内皮生长因子（VEGF）的重组融合蛋白，已被批准用于治疗转移性结直肠癌。其分子结构与阿柏西普（Eylea）相同，因此使其成为脉络膜视网膜血管疾病非适应证治疗的一个有吸引力的选择。阿柏西普以4毫升和8毫升的小瓶包装供静脉使用，混合后的成本与贝伐单抗相似。视网膜色素上皮细胞毒性研究、动物组织切片和视网膜电图研究均证实了其安全性，数学模型结合来自全球不同眼科中心的四十多篇临床出版物证明了其有效性。1.25毫克（0.05毫升）和2.5毫克（1.0毫升）剂量之间在视力或解剖学结果方面未发现明显差异。作用时间长且成本低，使得阿柏西普成为一种有吸引力的抗VEGF治疗选择，尤其是在其受欢迎程度不断提高的低收入和中等收入国家。
